Clinical Trial Update: Ruxolitinib and Decitabine for High Risk Hematological Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating ruxolitinib and decitabine for high risk hematological malignancies in the peripheral blood stem cell transplantation setting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies
• Peripheral Blood Stem Cell Transplantation Related Conditions

Drugs mentioned

• Decitabine (Decitabine)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Peripheral Blood Stem Cell Transplantation | Phase 1, Phase 2 | Status: UNKNOWN